HFB3024

About HiFiBiO Therapeutics

HiFiBiO Therapeutics, founded in 2017 and based in Cambridge, USA, is a private biotechnology company advancing a pipeline of immunotherapies in immuno-oncology and inflammatory/immunological diseases. Its core asset is the DIS® platform, a data-driven engine combining high-resolution single-cell analysis with computational biology to deconvolute disease biology and accelerate therapeutic development. The company has demonstrated strong translational capabilities, with multiple INDs cleared and programs in Phase 1 trials, supported by a broad network of over 12 strategic partnerships.

Therapeutic Areas

Other Inflammatory & Immunological Drugs